Kimia Farma Tbk PT
IDX:KAEF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Kimia Farma Tbk PT
Note Receivable
Kimia Farma Tbk PT
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kimia Farma Tbk PT
IDX:KAEF
|
Note Receivable
Rp147.6B
|
CAGR 3-Years
270%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
108%
|
|
|
T
|
Tempo Scan Pacific Tbk PT
IDX:TSPC
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kalbe Farma Tbk PT
IDX:KLBF
|
Note Receivable
Rp384.3B
|
CAGR 3-Years
60%
|
CAGR 5-Years
61%
|
CAGR 10-Years
16%
|
|
|
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
|
Note Receivable
Rp9.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Soho Global Health Tbk PT
IDX:SOHO
|
Note Receivable
Rp0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pyridam Farma Tbk PT
IDX:PYFA
|
Note Receivable
Rp23.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Kimia Farma Tbk PT
Glance View
PT Kimia Farma Tbk engages in the production and distribution of healthcare products. The company is headquartered in Jakarta, Dki Jakarta and currently employs 11,668 full-time employees. The company went IPO on 2001-07-04. The firm produces medical devices and chemical materials. The firm is also involved in producing vegetable oil, iodine, and salts. Its products include Glucokaf, Diazink, Oracef, Kifarox, Magacid Suspension, Magaside Chewable Tablets, Nitrocafe Retarded, Nitrocafe Retard Forte, Trinolon, Raistine, VAGIZOL, Neviral, Hiviral Tablet, Duviral, Codipront Cum Expectorant, RETHAPHYL SR, and SUPRAFLU. Its generic products include PETHIDIN Hcl, PARACETAMOL, Diclofenac Sodium, MEPHANAMIC ACID, ANTALGIN, ANTASIDE DOEN, PYRANTEL, ALBENDAZOLE, METRONIDAZOLE TABLET, NEO BLOOD ADDING TABLET, FERROUS SULOATE SYRUP, DIMENHYDRINATE, ACYCLOVIR, AMBROXOL HCL, CHLOROQUINE, CHLORPROMAZINE HCL, CODEIN, CLOPIDOGREL, ERGOTAMINE COFFEE, METHYLERGOMETRINE TABLET SALUTE, MELOXICAM, and Pherphenazine.
See Also
What is Kimia Farma Tbk PT's Note Receivable?
Note Receivable
147.6B
IDR
Based on the financial report for Dec 31, 2025, Kimia Farma Tbk PT's Note Receivable amounts to 147.6B IDR.
What is Kimia Farma Tbk PT's Note Receivable growth rate?
Note Receivable CAGR 10Y
108%
Over the last year, the Note Receivable growth was 223%. The average annual Note Receivable growth rates for Kimia Farma Tbk PT have been 270% over the past three years , and 108% over the past ten years .
